A CRISPR-Cas9 rendszerrel végzett genomszerkesztés módszere és onkológiai alkalmazásai

Translated title of the contribution: Genome engineering using the CRISPR-Cas9 system and applications in cancer research

Viktória Hudacsek, B. Györffy

Research output: Contribution to journalArticle

Abstract

Today, we have to investigate the effects of selected mutations and molecular alterations - this is made possible by the new genome editing technologies. In these, either a section of the DNA is deleted or moved, or a targeted mutation is introduced into the cell. Here, we describe in detail the CRISPR-Cas9 genome editing method. The technology is based on a feature used by bacteria to combat recurrent viral infections. At present, commencing a set of modifications, the method is functional and can be applied in eukaryotic cells as well. The method has three major steps: first, the system has to be carefully designed and constructed, then the construct has to be introduced into the target cells by transfection, and finally, the achieved effect has to be functionally validated. The reliability of the method enables multiple applications in oncology, including the detailed and efficient investigation of oncogenes, tumor suppressor genes, chromosomal translocations and other molecular changes. At the moment, available CRISPR-Cas9 protocols enable both in vitro and in vivo application. All these already made CRISPR-Cas9 one of the basic methods required for future-proof oncology research.

Original languageHungarian
Pages (from-to)119-127
Number of pages9
JournalMagyar onkologia
Volume62
Issue number2
Publication statusPublished - Jul 20 2018

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Genome
Research
Neoplasms
Technology
Genetic Translocation
Mutation
Eukaryotic Cells
Virus Diseases
Tumor Suppressor Genes
Oncogenes
Transfection
Bacteria
DNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A CRISPR-Cas9 rendszerrel végzett genomszerkesztés módszere és onkológiai alkalmazásai. / Hudacsek, Viktória; Györffy, B.

In: Magyar onkologia, Vol. 62, No. 2, 20.07.2018, p. 119-127.

Research output: Contribution to journalArticle

@article{b3159fb7b14d43e498442c2ed020de37,
title = "A CRISPR-Cas9 rendszerrel v{\'e}gzett genomszerkeszt{\'e}s m{\'o}dszere {\'e}s onkol{\'o}giai alkalmaz{\'a}sai",
abstract = "Today, we have to investigate the effects of selected mutations and molecular alterations - this is made possible by the new genome editing technologies. In these, either a section of the DNA is deleted or moved, or a targeted mutation is introduced into the cell. Here, we describe in detail the CRISPR-Cas9 genome editing method. The technology is based on a feature used by bacteria to combat recurrent viral infections. At present, commencing a set of modifications, the method is functional and can be applied in eukaryotic cells as well. The method has three major steps: first, the system has to be carefully designed and constructed, then the construct has to be introduced into the target cells by transfection, and finally, the achieved effect has to be functionally validated. The reliability of the method enables multiple applications in oncology, including the detailed and efficient investigation of oncogenes, tumor suppressor genes, chromosomal translocations and other molecular changes. At the moment, available CRISPR-Cas9 protocols enable both in vitro and in vivo application. All these already made CRISPR-Cas9 one of the basic methods required for future-proof oncology research.",
author = "Vikt{\'o}ria Hudacsek and B. Gy{\"o}rffy",
year = "2018",
month = "7",
day = "20",
language = "Hungarian",
volume = "62",
pages = "119--127",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - A CRISPR-Cas9 rendszerrel végzett genomszerkesztés módszere és onkológiai alkalmazásai

AU - Hudacsek, Viktória

AU - Györffy, B.

PY - 2018/7/20

Y1 - 2018/7/20

N2 - Today, we have to investigate the effects of selected mutations and molecular alterations - this is made possible by the new genome editing technologies. In these, either a section of the DNA is deleted or moved, or a targeted mutation is introduced into the cell. Here, we describe in detail the CRISPR-Cas9 genome editing method. The technology is based on a feature used by bacteria to combat recurrent viral infections. At present, commencing a set of modifications, the method is functional and can be applied in eukaryotic cells as well. The method has three major steps: first, the system has to be carefully designed and constructed, then the construct has to be introduced into the target cells by transfection, and finally, the achieved effect has to be functionally validated. The reliability of the method enables multiple applications in oncology, including the detailed and efficient investigation of oncogenes, tumor suppressor genes, chromosomal translocations and other molecular changes. At the moment, available CRISPR-Cas9 protocols enable both in vitro and in vivo application. All these already made CRISPR-Cas9 one of the basic methods required for future-proof oncology research.

AB - Today, we have to investigate the effects of selected mutations and molecular alterations - this is made possible by the new genome editing technologies. In these, either a section of the DNA is deleted or moved, or a targeted mutation is introduced into the cell. Here, we describe in detail the CRISPR-Cas9 genome editing method. The technology is based on a feature used by bacteria to combat recurrent viral infections. At present, commencing a set of modifications, the method is functional and can be applied in eukaryotic cells as well. The method has three major steps: first, the system has to be carefully designed and constructed, then the construct has to be introduced into the target cells by transfection, and finally, the achieved effect has to be functionally validated. The reliability of the method enables multiple applications in oncology, including the detailed and efficient investigation of oncogenes, tumor suppressor genes, chromosomal translocations and other molecular changes. At the moment, available CRISPR-Cas9 protocols enable both in vitro and in vivo application. All these already made CRISPR-Cas9 one of the basic methods required for future-proof oncology research.

UR - http://www.scopus.com/inward/record.url?scp=85066473897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066473897&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 119

EP - 127

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -